{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:30:57Z","timestamp":1770975057256,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Public Health"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.puhe.2021.03.017","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T04:50:55Z","timestamp":1622091055000},"page":"42-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia"],"prefix":"10.1016","volume":"195","author":[{"given":"Ketevan","family":"Stvilia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nino","family":"Vephkvadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amiran","family":"Gamkrelidze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irma","family":"Khonelidze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimer","family":"Getia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9736-0357","authenticated-orcid":false,"given":"Maia","family":"Tsereteli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2574-3957","authenticated-orcid":false,"given":"Lia","family":"Gvinjilia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tinatin","family":"Kuchuloria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.puhe.2021.03.017_bib1","series-title":"World drug report 2020, drug use and health consequences","year":"2020"},{"key":"10.1016\/j.puhe.2021.03.017_bib2","series-title":"Miles to go: closing gaps, breaking barriers, righting injustices, UNAIDS","year":"2018"},{"key":"10.1016\/j.puhe.2021.03.017_bib3","series-title":"European Monitoring Center for Drugs and Drug Addiction (EMCDDA), European drug report 2019: trends and developments","year":"2019"},{"key":"10.1016\/j.puhe.2021.03.017_bib4","series-title":"International standards for the treatment of drug use disorders: revised edition incorporating results of field-testing","year":"2020"},{"key":"10.1016\/j.puhe.2021.03.017_bib5","series-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.puhe.2021.03.017_bib6","series-title":"Bio-behavioral surveillance survey among people who inject drugs in seven cities of Georgia","author":"Curatio International Foundation","year":"2017"},{"key":"10.1016\/j.puhe.2021.03.017_bib7","series-title":"Hepatitis C fact sheet","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.puhe.2021.03.017_bib8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12889-019-6784-3","article-title":"Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination","volume":"19","author":"Hagan","year":"2019","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.puhe.2021.03.017_bib9","series-title":"Access to hepatitis C treatment in Eastern Europe and Central Asia","author":"Kravchenko","year":"2017"},{"key":"10.1016\/j.puhe.2021.03.017_bib10","series-title":"Strategic plan to eliminate hepatitis C in Georgia, 2016-2020","year":"2015"},{"key":"10.1016\/j.puhe.2021.03.017_bib11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.15585\/mmwr.mm6541a2","article-title":"National progress toward hepatitis C elimination\u2014Georgia, 2015\u20132016","volume":"65","author":"Gvinjilia","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.puhe.2021.03.017_bib12","series-title":"Georgia ministry of internally displaced persons from the occupied territories, labour, health, and social affairs","year":"2019"},{"key":"10.1016\/j.puhe.2021.03.017_bib13","article-title":"HCV screening among the population of Georgia within the National Elimination Program. Poster Presentation","author":"Sergeenko","year":"2018","journal-title":"J\u00a0Hepat Euro Assoc Study Liver"},{"key":"10.1016\/j.puhe.2021.03.017_bib14","article-title":"Dore, Clinical,Treatment of HCV in persons who inject drugs: treatment as prevention liver disease","author":"Grebely","year":"2017","journal-title":"Multimedia Rev J"},{"key":"10.1016\/j.puhe.2021.03.017_bib15","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.drugpo.2015.07.005","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"26","author":"Grebely","year":"2015","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.puhe.2021.03.017_bib16","series-title":"Recommendations for testing, managing, and treating hepatitis C","year":"2015"},{"key":"10.1016\/j.puhe.2021.03.017_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.puhe.2021.03.017_bib18","series-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection","year":"2018"},{"key":"10.1016\/j.puhe.2021.03.017_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/infdis\/jir196","article-title":"A\u00a0systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs","volume":"204","author":"Hagan","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.puhe.2021.03.017_bib20","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/j.1360-0443.2011.03515.x","article-title":"The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence","volume":"106","author":"Turner","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.puhe.2021.03.017_bib21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis","volume":"113","author":"Platt","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.puhe.2021.03.017_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12954-016-0124-z","volume":"13","author":"Ruadze","year":"2016","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.puhe.2021.03.017_bib23","series-title":"Annual MST program report","year":"2018"},{"issue":"11","key":"10.1016\/j.puhe.2021.03.017_bib24","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.drugpo.2015.04.015","article-title":"An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: structural barriers and public health potential","volume":"26","author":"Perlman","year":"2015","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.puhe.2021.03.017_bib25","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis","volume":"57","author":"Aspinall","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.puhe.2021.03.017_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/jhep.2001.25882","article-title":"Treatment of hepatitis C infection in injection drug users","volume":"34","author":"Backmund","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.puhe.2021.03.017_bib27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/600304","article-title":"Hepatitis C treatment for injection drug users: a review of the available evidence","volume":"49","author":"Hellard","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.puhe.2021.03.017_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00042737-200602000-00008","article-title":"Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes","volume":"18","author":"Robaeys","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.puhe.2021.03.017_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2036.2008.03834.x","article-title":"Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use","volume":"29","author":"Wilkinson","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.puhe.2021.03.017_bib30","author":"AASLD-IDSA"},{"key":"10.1016\/j.puhe.2021.03.017_bib31","first-page":"19","article-title":"An update on the management of chronic hepatitis C: 2015 Consensus Guidelines from the Canadian Association for the Study of the Liver","volume":"29","author":"Myers","year":"2015","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"10.1016\/j.puhe.2021.03.017_bib32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.puhe.2021.03.017_bib33","first-page":"697","article-title":"Economic evaluation of HCV testing approaches in low and middle income countries","volume":"17","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.puhe.2021.03.017_bib34","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1360-0443.2012.03932.x","article-title":"Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings","volume":"107","author":"Vickerman","year":"2012","journal-title":"Addiction"},{"issue":"Suppl 2","key":"10.1016\/j.puhe.2021.03.017_bib35","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"Martin","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.puhe.2021.03.017_bib36","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/cid\/ciz714","article-title":"The consensus hepatitis C cascade of care: standardized reporting to monitor progress toward elimination","volume":"69","author":"Safreed-Harmon","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.puhe.2021.03.017_bib37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jhep.2019.06.026","article-title":"Excellence in viral hepatitis elimination\u2013Lessons from Georgia","volume":"71","author":"Averhoff","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.puhe.2021.03.017_bib38","series-title":"Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality","author":"Cramp","year":"2014"},{"issue":"Suppl 1","key":"10.1016\/j.puhe.2021.03.017_bib39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/jvh.12249","article-title":"Strategies to manage hepatitis C virus (HCV) disease burden","volume":"21","author":"Wedemeyer","year":"2014","journal-title":"J\u00a0Viral Hepat"},{"issue":"No. RR-2","key":"10.1016\/j.puhe.2021.03.017_bib40","first-page":"1","article-title":"CDC recommendations for Hepatitis C Screening Among Adults \u2014 United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.puhe.2021.03.017_bib41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.15585\/mmwr.mm6428a2","article-title":"World hepatitis day\u2014July 28, 2015 launch of a Nationwide Hepatitis C Elimination Program\u2014","volume":"64","author":"Mitruka","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.puhe.2021.03.017_bib42","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1186\/1471-2334-14-S6-S16","article-title":"A\u00a0systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region","volume":"14","author":"Lazarus","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.puhe.2021.03.017_bib43","series-title":"Compendium of good practices in the health sector response to HIV in the WHO European Region","first-page":"p36","year":"2018"},{"issue":"Suppl 2","key":"10.1016\/j.puhe.2021.03.017_bib44","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis","volume":"57","author":"Aspinall","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.puhe.2021.03.017_bib45","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/600304","article-title":"Hepatitis C treatment for injection drug users: a review of the available evidence","volume":"49","author":"Hellard","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.puhe.2021.03.017_bib46","series-title":"Access to hepatitis C testing and treatment for people who inject drugs and people in prisons \u2013 a global perspective: policy brief","author":"World Health Organization","year":"2019"},{"issue":"Suppl 1","key":"10.1016\/j.puhe.2021.03.017_bib47","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.drugpo.2014.08.014","article-title":"Prevention, treatment and care of hepatitis C virus infection among people who inject drugs","volume":"26","author":"Bruggmann","year":"2015","journal-title":"Int J Drug Pol"},{"issue":"6","key":"10.1016\/j.puhe.2021.03.017_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178398","article-title":"Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: no effect of recent or former injecting drug use on treatment adherence or therapeutic response","volume":"12","author":"Elsherif","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.puhe.2021.03.017_bib49","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugpo.2017.05.025","article-title":"Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community based program in Toronto, Canada","volume":"47","author":"Mason","year":"2017","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.puhe.2021.03.017_bib50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.drugpo.2018.07.016","article-title":"Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: a prospective cohort study","volume":"62","author":"Bouscaillou","year":"2018","journal-title":"Int J Drug Pol"},{"issue":"Suppl 1","key":"10.1016\/j.puhe.2021.03.017_bib51","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.drugpo.2014.08.014","article-title":"Prevention, treatment and care of hepatitis C virus infection among people who inject drugs","volume":"26","author":"Bruggmann","year":"2015","journal-title":"Int J Drug Pol"},{"issue":"10","key":"10.1016\/j.puhe.2021.03.017_bib52","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.drugpo.2015.07.005","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"26","author":"Grebely","year":"2015","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.puhe.2021.03.017_bib53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/apc.2006.0206","article-title":"A\u00a0qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV","volume":"22","author":"Lally","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.puhe.2021.03.017_bib54","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1089\/apc.2010.0142","article-title":"Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration","volume":"24","author":"Swan","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.puhe.2021.03.017_bib55","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1177\/002204260803800411","article-title":"Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs","volume":"38","author":"Strauss","year":"2008","journal-title":"J\u00a0Drug Issues"},{"key":"10.1016\/j.puhe.2021.03.017_bib56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.socscimed.2013.01.031","article-title":"Taming systems to create enabling environments for HCV treatment: negotiating trust in the drug and alcohol setting","volume":"83","author":"Harris","year":"2013","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.puhe.2021.03.017_bib57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/09687630500481150","article-title":"HCV and injecting-related discrimination in New South Wales, Australia","volume":"13","author":"Hopwood","year":"2006","journal-title":"Drugs Educ Prev Pol"},{"issue":"4","key":"10.1016\/j.puhe.2021.03.017_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216123","article-title":"On the way to hepatitis C elimination in the Republic of Georgia\u2014barriers and facilitators for people who inject drugs for engaging in the treatment program: a formative qualitative study","volume":"14","author":"Chikovani","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.puhe.2021.03.017_bib59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/M15-0617","article-title":"Prevention of hepatitis C by screening and treatment in U.S. Prisons","volume":"164","author":"He","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.puhe.2021.03.017_bib60","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/add.13783","article-title":"Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland","volume":"112","author":"Stone","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.puhe.2021.03.017_bib61","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/COH.0000000000000179","article-title":"The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention","volume":"10","author":"Martin","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.puhe.2021.03.017_bib62","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1056\/NEJMp1311941","article-title":"Responding to hepatitis C through the criminal justice system","volume":"370","author":"Rich","year":"2014","journal-title":"N\u00a0Engl J Med"}],"container-title":["Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033350621001268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033350621001268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:34:47Z","timestamp":1758501287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033350621001268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":62,"alternative-id":["S0033350621001268"],"URL":"https:\/\/doi.org\/10.1016\/j.puhe.2021.03.017","relation":{},"ISSN":["0033-3506"],"issn-type":[{"value":"0033-3506","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia","name":"articletitle","label":"Article Title"},{"value":"Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.puhe.2021.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}